STAT+: UnitedHealth’s questionable review, and more MA stars lawsuits

STAT PlusNewsletterHealth Care Inc. Newsletter UnitedHealth’s questionable review, and more MA stars lawsuits You’re reading STAT’s Health Care Inc. newsletter Manage alerts for this article Email this article Share this article By Bob HermanJuly 13, 2026 Business of Health Care Reporter Bob Herman[email protected]Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. I first visited a Buc-ee’s a few years ago in Kentucky on a road trip. It’s a melting pot of American culture and consumerism (with a really good cherry limeade pop). It’s also apparently an aggressive trademark litigator over its beaver mascot. Take a pit stop and share your news and tips here: [email protected].Advertisement [Tim Robinson voice] You sure about that? UnitedHealth Group was happy to promote a new audit that said nearly all of the diagnoses recorded for its Medicare Advantage members during home visits (97%) were justified by medical records. But the results are not nearly as clean, or useful, as the company suggests. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug development, government agencies, Health insurance, insurance, legal, medicare advantage, Policy, STAT+ Submit a correction requestReprints Bob Herman Business of Health Care Reporter Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. Newsletter Unpacking the business — and secretive inner workings — of the U.S. health care industry Recommended The Readout July 13, 2026 STAT Plus: All eyes on data on Biogen’s tau therapy Biotech July 12, 2026 STAT Plus: Tau in the spotlight at Alzheimer’s conference Advertisement The Readout July 10, 2026 STAT Plus: Roche ends Huntington’s gene-silencing programs D.C. Diagnosis July 9, 2026 STAT Plus: FDA finalists under review The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Subscriber Picks